Two key catalysts for US listing:
Smaller pieces of news such as the preclinical work for Breast Cancer, published paper and abstract for Israel trial and even the video updates they are planning to release will support the story.
- Obviously the Texas trial would get attention in the US market so any positive news (about the planning, about the grant or the start of the trial)
- The Breast Cancer trial due to the scale of the potential market
RAC are planning to submit an abstract of the ASH conference. That could really get attention in the US ... so I am now thinking important to get a listing set up before that abstract is submitted/released.
https://www.hematology.org/meetings/annual-meeting
Abstract submissions for ASH 2020 are open but they will need to wait until Sheba has published the trial results in their own peer-reviewed paper. RAC will need to update market when both events occur.
https://www.hematology.org/meetings/annual-meeting/2020-call-for-abstracts
RAC Research Primer - June 2020, page-135
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |